VAQTA Suspension for Injection in Pre-filled Syringe
Hepatitis A Virus (Inactivated) Vaccine
50 IU/ml
BAXALTA INNOVATIONS GmbH
| Pack size | 1 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 114.00 AED |
Indications
VAQTA Suspension for Injection in Pre-filled Syringe is used for:
Active immunization against Hepatitis A virus.
Hepatitis A vaccine is used to prevent, hepatitis A
Adult Dose
Intramuscular
Active immunisation against hepatitis A
Adult:
First dose: At selected date
Second dose: 6 months after first dose
Child Dose
Intramuscular
Active immunisation against hepatitis A
Children of 1 year of age
First dose: At selected date
Second dose: 6 months after first dose
Children 12 months to 15 years: The recommended dose is 0.5 ml
First dose: At selected date
Second dose: 6 months after first dose
Children 16 years and above: The recommended dose is 1 ml
First dose: At elected date
Second dose: 6 months after first dose
Renal Dose
Administration
Hepatitis A vaccine should be given intramuscularly only.
Contra Indications
Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.
Precautions
Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.
The vaccine should be given to a pregnant woman only if clearly needed.
Lactation: not established
Pregnancy-Lactation
Pregnancy Category: C
Lactation: not established
Interactions
Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Adverse Effects
Side effects of Hepatitis A Virus (Inactivated) Vaccine :
>10%
Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%), Irritability (11-36%), Anorexia (1-19%), Drowsiness (15-17%), Headache (1-16%), Fever > 100.4 F (9-11%)
1-10%
URI (1-10%), Otitis media (8%), Rhinorrhea (6%), Diarrhea (1-6%), Cough (1-5%), Rash (1-5%), Weakness/fatigue (4%), Vomiting (1-4%), Fever > 102 F (3%), Crying (2%)
<1%
Hematoma, Incr. CPK, Photophobia, Vertigo
Potentially Fatal: Anaphylaxis.
Mechanism of Action
Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.
Note
VAQTA 50 IU/ml Suspension for Injection in Pre-filled Syringe manufactured by BAXALTA INNOVATIONS GmbH. Its generic name is Hepatitis A Virus (Inactivated) Vaccine. VAQTA is availble in Saudi Arabia.
Farmaco SA drug index information on VAQTA Suspension for Injection in Pre-filled Syringe is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.